Background The primary aims of this trial are to determine whether the use of a concomitant prophylactic anti-incontinence procedure may prevent stress urinary incontinence symptom development in women undergoing vaginal prolapse surgery and to evaluate the cost-effectiveness of this prophylactic approach. Purpose To present the rationale and design of a randomized controlled surgical trial (RCT), the Outcomes following vaginal Prolapse repair and mid Urethral Sling (OPUS) Trial highlighting the challenges in the design and implementation. Methods The challenges of implementing this surgical trial combined with a costeffectiveness study and patient preference group are discussed including the study design, ethical issues regarding use of sham incision, maintaining the masking of study staff, and pragmatic difficulties encountered in the collection of cost data. The trial is conducted by the NICHD-funded Pelvic Floor Disorders Network. Results The ongoing OPUS trial started enrollment in May 2007 with a planned accrual of 350. The use of sham incision was generally well accepted but the collection of cost data using conventional billing forms was found to potentially unmask key study personnel. This necessitated changes in the study forms and planned timing for collection of cost data. To date, the enrollment to the patient preference group has been lower than the limit established by the protocol suggesting a willingness on the part of women to participate in the randomization. Limitations Given the invasive nature of surgical intervention trials, potential participants may be reluctant to accept random assignment, potentially impacting generalizability. Conclusion Findings from the OPUS trial will provide important information that will help surgeons to better counsel women on the benefits and risks of concomitant prophylactic anti-incontinence procedure at the time of vaginal surgery for prolapse. The implementation of the OPUS trial has necessitated that investigators consider ethical issues up front, remain flexible with regards to data collection and be constantly aware of unanticipated opportunities for unmasking. Future surgical trials should be aware of potential challenges in maintaining masking and collection of cost-related information. Clinical Trials 2009; 6: 162-171.
Introduction
Pelvic floor disorders, particularly pelvic organ prolapse (a condition in which the uterus, vagina, bladder, and/or rectum bulge into or outside of the vagina) and urinary incontinence (involuntary urinary leakage), are common in women. One in nine American women will undergo at least one surgery for pelvic organ prolapse or urinary incontinence by the age of 80. More distressingly, 30% of those will undergo at least one additional surgery [1] .
Some women with advanced pelvic organ prolapse remain continent despite significant loss of anterior vaginal and pelvic organ support. The prolapse may function to kink the urethra, maintaining continence by causing urethral obstruction [2] . It is not uncommon for continent women undergoing prolapse surgery to develop de novo stress urinary incontinence (leakage with physical exertion such as coughing or exercise) postoperatively. This may result from relieving the urethral obstruction caused by prolapse, thereby unmasking a preexisting compromised urethra. Some have referred to this as an unmasking of occult or potential stress urinary incontinence [3] .
Postoperative stress urinary incontinence may also result from compromised urethral innervation or support secondary to the surgical repair.
The Pelvic Floor Disorders Network, a Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)-sponsored clinical trials network, recently conducted a randomized surgical trial (the Colpopexy and Urinary Reduction Efforts (CARE) trial) to address whether adding an anti-incontinence procedure at the time of an abdominal prolapse surgery reduced postoperative stress urinary incontinence in women without such leakage prior to surgery. In this trial, women who were randomized to a concomitant retropubic anti-incontinence procedure (Burch colposuspension) had approximately half the rate of stress urinary incontinence as did women who underwent only abdominal sacrocolpopexy for prolapse (24% vs. 44%, p < 0.001) but experienced no increase in adverse outcomes [4] .
Whether similar benefits occur with the addition of an anti-incontinence procedure at the time of vaginal surgery for prolapse in stress continent women is not known. However, many surgeons are performing prophylactic anti-incontinence procedures, notably placement of midurethral slings, at the time of vaginal prolapse surgery. This practice is supported by a single, small randomized controlled trial (RCT) of 50 women in which 4% of subjects who received an anti-incontinence sling procedure and 36% of those who did not, reported stress urinary incontinence two years after surgery (p ¼ 0.01) [5] . In contrast, a separate retrospective study of 76 women with prolapse surgery but who did not undergo a prophylactic anti-incontinence procedure reported stress urinary incontinence in only 7% with a median follow-up of 23 months [6] . The results of a transvaginal approach for prolapse repair and vaginal anti-incontinence procedure (midurethral sling) may differ from those procedures performed for the same indications through an abdominal approach. Such differences may lead to disparate efficacy and complication rates. Thus, women undergoing a midurethral sling may be at lower risk of stress leakage but at higher risk of adverse outcomes such as urinary urgency, voiding difficulties, and sling mesh erosion. Moreover, the cost of midurethral slings adds considerably to the overall cost of prolapse repair, raising the issue of cost-effectiveness of such a prophylactic approach.
In order to estimate the efficacy, adverse outcomes, and cost-effectiveness of performing a prophylactic mid-urethral sling procedure in stress-continent women undergoing vaginal surgery for prolapse, the Outcomes following vaginal Prolapse repair and mid Urethral Sling (OPUS) trial was implemented. The purpose of this paper is to describe the design of the trial, highlighting the difficulties encountered in the design and implementation of a surgical sham group, a patient preference group (PPG), and collection of cost data.
Methods
The pelvic floor disorders network
The Pelvic Floor Disorders Network, formed in 2001 to conduct research and clinical trials focusing on pelvic organ prolapse and bladder and bowel control conditions, currently consists of seven clinical sites (see appendix) and a data coordinating center at the University of Michigan where there is no clinical site. A steering committee, consisting of the principal investigator (PI) of each clinical site, the PI of the data coordinating center, and the NIH program scientist, identifies and selects potential topics for clinical trials. Each member of the committee has one vote. The committee votes on the progression of a clinical trial protocol from concept to implementation by secret ballot; a 75% majority steering committee vote is necessary for a randomized clinical trial to be implemented. The steering committee meets monthly either in person (quarterly) or by conference call. The study coordinators and coinvestigators also participate in these monthly calls/meetings. An advisory board serves an external peer review function and provides feedback on the scientific merit to the investigators and the NICHD. An independent data and safety monitoring board (DSMB) reviews protocols with respect to ethical and safety standards, monitors the safety of ongoing clinical trials, and provides advice on study conduct. Each clinical site and the data coordinating center have obtained IRB approval, and written informed consent is obtained from each participant prior to enrollment. Enrollment began in May 2007 and is estimated to be completed by April 2009. This study is registered at www.clinicaltrials.gov (NCT00460434). Figure 1 depicts the OPUS trial design. We hypothesize that stress-continent women undergoing vaginal prolapse surgery who receive a concomitant tension-free vaginal tape procedure will have lower prevalence of and less treatment for bothersome urinary incontinence during the first 3 months following surgery and that the overall healthcare cost and quality of life will be similar between the 2 groups at 12 months after the index surgery. The primary study aims are to (1) test whether the prevalence of postoperative urinary incontinence differs between stress-continent women undergoing vaginal prolapse repair with concomitant tension-free vaginal tape and those undergoing vaginal prolapse repair with only sham incisions (i.e., no anti-incontinence procedure) at 3 months post index surgery; (2) evaluate whether prevalence of bothersome urinary incontinence at 12 months following index surgery differs between the two groups; and (3) compare the cost-effectiveness of performing concomitant tension-free vaginal tape at the time of vaginal prolapse repair for stress-continent women versus expectant treatment of urinary incontinence if it occurs postoperatively (i.e., a 'wait and see' UI = urinary incontinence, TVT ® = tension-free vaginal tape. *Women otherwise eligible but who choose an alternative prophylaxis to TVT ® cannot be enrolled in PPG. The study is a randomized, single-blind, shamcontrolled surgical intervention trial. Both the control and experimental groups will undergo vaginal prolapse repair, while the experimental group will receive concomitant tension-free vaginal tape. Assignment to study arms will be randomly allocated in a 1:1 ratio. A systematic sample of those declining participation in the RCT, who are otherwise eligible for the study, will be offered participation in the patient preference group (PPG). The PPG will therefore also have two groups-those who undergo a tension-free vaginal tape at the time of prolapse surgery and those who do not. The PPG will be used to quantify sample selection bias due to RCT nonparticipation. Potentially important differences in demographics, clinical characteristics and outcomes between the RCT and PPG samples will be examined, stratified by surgeon and treatment received. Inclusion and exclusion criteria for the PPG are otherwise identical to those of the RCT, except for willingness to be randomized. In order to minimize selection bias due to the availability of the PPG itself, the PPG will only be offered to the participant once she has explicitly declined participation in the RCT. The PPG will be limited to 3 participants per every 5 enrolled in the RCT, per clinical site, up to a total of 115 per arm.
Design overview

Study population
Participants will consist of women being considered for an apical and/or anterior vaginal prolapse repair via a vaginal approach without subjective reporting of stress urinary incontinence. Participants must have vaginal bulge symptoms defined by positive responses to a validated instrument, the Pelvic Floor Distress Inventory [7] and anterior vaginal prolapse (i.e., loss of anterior vaginal support implying the urethra is not supported behind the pubic bone) as determined by the Pelvic Organ Prolapse Quantification (POPQ) system [8] , a validated tool designed to assess the degree of vaginal prolapse. The complete list of inclusion and exclusion criteria is summarized in Table 1 .
Pre-intervention assessments
All women presenting to the participating Pelvic Floor Disorders Network clinical centers with a finding of prolapse will be screened for their eligibility. If eligible and consenting, the following baseline data are collected: demographics, POPQ values, cough stress test, postvoid residual volume, general health and urogynecological history, and health-related quality of life. The cough stress test is performed at a retrograde bladder fill volume of 300 cc or maximum bladder capacity, whichever is lower. The participant, initially in the lithotomy position, is instructed to first bear down maximally and then cough hard several times while the research nurse observes the urethral meatus for urine leakage. Regardless of leakage, the test is then repeated while the nurse reduces the prolapse with two large swabs in supporting the vaginal apex. If no leakage is evident, the test is repeated in a standing position with the prolapse reduced. A series of instruments will be used to measure health-related quality of life: the Medical Outcome Study Short-Form-36 Health Survey (SF-36) [9] , EuroQol (EQ-5D) [10] , Pelvic Floor Distress Inventory [7] , Pelvic Floor Impact Questionnaire [7] , Incontinence Severity Index (ISI) [11] , Pelvic Organ Prolapse/Urinary Incontinence Sexual Functioning Questionnaire Short Form (PISQ-12) [12] , Pelvic Floor Disorders Network Adaptations Index [13] , an analog pain scale adapted for suprapubic pain [14] , and the Patient Global Impression of Improvement (PGI-I) Scale [15] . The telephone assessment of health-related quality of life will be performed by female interviewers masked to group assignment at a centralized quality of life interviewing center. Medical data will be obtained by clinical sites using standardized data collection forms. Surgeons will be blinded to the cough stress test results.
Randomization and masking
A Randomization, using a random block design, will be stratified by surgeon (approximately 30) and category of planned surgery (4), which includes colpocleisis (a type of vaginal closure), apical support procedure, and/or anterior repair procedure. Randomization will be assigned in the operating room to minimize surgeon and participant bias. While it is impossible for surgeons to be masked to the randomization, participants and research staff will be masked during the one-year follow-up period. Dictated operative notes will describe the actual procedure(s) performed; however, the handwritten chart note will indicate the surgery by stating, ''transvaginal procedure as per OPUS trial protocol; see the dictated operative report.'' Precautions will be taken to minimize unmasking the tension-free vaginal tape procedure. Since tension-free vaginal tape requires two 1-cm suprapubic incisions, the control group will receive comparable sham incisions and the surgical wound dressings will be identical for all participants. Intraoperative data, which may unmask the study coordinators, will be reported by the surgeon directly to the data coordinating center. Finally, all participants regardless of randomization, will have postoperative indwelling urethral catheters until voiding trials are performed.
Study intervention
The primary intervention, or surgical technique, is the tension-free vaginal tape (Ethicon; Johnson & Johnson) anti-incontinence procedure. Prolapse procedures will be recorded but not controlled by study protocol. Participating surgeons are required to have performed at least 20 tension-free vaginal tape procedures prior to enrolling participants in OPUS. In order to minimize the risk of altering the urethrovesical angle and the likelihood of postoperative stress urinary incontinence, the anterior repair will be conducted using only one incision proximal to the bladder neck level and separate from tension-free vaginal tape incisions. Allowable techniques for anterior vaginal wall prolapse repair include anterior colporrhaphy (plication of vesicovaginal fibromuscular tissue), vaginal paravaginal repair, colpocleisis, and use of allograft, xenograft, or synthetic graft material. Plication of periurethral fibromuscular tissue (''Kelly'' or suburethral plication) or placement of any sutures near the urethra or bladder neck is not allowable.
Post-intervention assessments
The primary endpoints will be assessed at 3 and 12 months after the index surgery via a clinic visit and health-related quality of life interview. The quality of life interviewing center will also assess health-related quality of life at 6 months while study coordinators will collect follow-up healthcare utilization data and update the medical history at 3, 6, 9, and 12 months.
Clinical outcomes
This trial has two primary outcomes. The first is defined at three months by a positive cough stress test and/or bothersome urinary incontinence (at least moderately bothersome positive responses to any of the first four items in Table 2 ) and/or need for urinary incontinence treatment. The second is identical to the first but measured at 12 months and will exclude additional urinary incontinence treatment criteria.
Secondary outcome measures will assess the degree to which the study intervention influences adverse events at 3 and 12 months and include pelvic organ prolapse, urinary tract infections, serious adverse events, and health-related quality of life.
Economic evaluation and analyses
The cost-effectiveness analysis, comparing the placement of a concomitant tension-free vaginal tape at the time of vaginal prolapse repair versus prolapse surgery alone, will be conducted from a societal perspective. Both direct medical and nonmedical costs and indirect costs (i.e., productivity loss) will be estimated. Information on resource use will be collected using each clinical site's billing records and participant self-report data. Direct medical costs include incremental costs of the index surgery associated with tension-free vaginal tape and subsequent use of urologic/urogynecologic-related medical services during the 12-month follow-up period. The Medicare reimbursement rate [16] will be used to assign unit cost for each type of medical service. Average wholesale prices recorded in the Drug Topics Red Book Õ [17] will be used as medication unit costs. Direct nonmedical costs include expenditures associated with incontinence care, such as absorbent pads, laundry and skin care products, and transportation for care of relevant urologic/gynecologic conditions or complications subsequent to the index surgery. Indirect costs will be estimated using data on days of work loss, household productivity loss, and reduced efficiency while at work due to complications of the index surgery and symptoms and treatment of urinary incontinence or other urologic/gynecologic conditions.
Patient-level quality-adjusted life years will be calculated assuming linear changes in each participant's utility scores over time between every two assessments and calculating the area under the curve over the 12-month period [18] . To assess incremental costs associated with each additional quality-adjusted life years gained, incremental costeffectiveness ratios will be calculated as the differential mean cost divided by the differential mean quality-adjusted life years between the two arms. The base case analysis will be conducted using data on participants with complete cost information and measures of quality-adjusted life years based on the EuroQol-5D [10] . Sensitivity analysis will be performed to include the information of participants with incomplete data using multiple imputation [19] and measures of quality-adjusted life years based on the Pelvic Floor Impact Questionnaire urinary incontinence scale [7] to shed light on the cost-effectiveness of the concomitant tension-free vaginal tape procedure when condition-specific utility scores are used. The nonparametric bootstrapping resampling technique [20] will be used to derive the 95% confidence interval for the incremental cost-effectiveness ratio.
Sample size
Surgery for prolapse has been associated with postoperative de novo stress urinary incontinence in 13% of women, but the inclusion of urge urinary incontinence would likely increase overall urinary incontinence to 20% [21] [22] [23] . A minimum of 300 participants (150 per group) will be randomized to detect a difference of 10% or more with 80% power to differentiate the two groups with respect to the primary outcome at 3 months of 20% and 35% using a two-tailed test with 5% level of significance. Approximately 350 participants will be randomized to allow for an estimated 15% loss to follow-up during the 12-month period.
Statistical analysis
Intent-to-treat analysis will be used to compare the primary outcome at three months between groups using a conditional logistic model. Dropouts will be considered as failures unless there is clear evidence that the reason for withdrawal or loss to follow-up was unrelated to the trial (e.g., accidental death). Table 2 The primary outcomes at 3 and 12 months based on the cough stress test, bothersome incontinence symptoms, and treatment(s) for urinary incontinence
months 12 months
A positive cough stress test Yes Yes Symptoms of bothersome urinary incontinence based on the following*:
Yes Yes 1. Do you usually experience urine leakage related to coughing, sneezing, or laughing? 2. Do you usually experience urine leakage related to physical exercise such as walking, running, aerobics, or tennis? 3. Do you usually experience urine leakage related to lifting or bending over? 4. Do you usually experience urine leakage associated with a feeling of urgency, that is, a strong sensation of needing to go to the bathroom?
Additional treatment for urinary incontinence (including sling, suspension surgery, collagen injections, supervised pelvic muscle therapy, medication, pessary)
Yes
Not applicable *Where a positive answer to any of the stress and/or urge urinary incontinence items above are also characterized as being at least moderately bothersome.
All models will be adjusted for the randomization stratification variables. In addition, we will estimate the difference in our primary outcomes and confidence intervals. The 12-month data will be analyzed in a similar manner except that the definition of the primary outcome will not include need for additional urinary incontinence treatment.
Discussion
Study design issues
Surgical decision making is complex, involving the desire to improve outcomes while minimizing complications and unnecessary procedures. Some surgeons perform prophylactic anti-incontinence procedures for all women undergoing prolapse surgery while others do not perform prophylactic anti-incontinence procedures, preferring to treat only those who develop bothersome stress urinary incontinence postoperatively. Failure to systematically evaluate surgical interventions may give rise to proliferation of expensive and possibly ineffective therapies with both financial and health impacts. In planning this trial, we debated whether to simply conduct a prevention trial for efficacy or to conduct an effectiveness trial that examined outcomes after allowing patients to obtain additional treatments. Although we considered a multiple-arm trial, this would have required a sample size exceeding the capacity of the current network. A compromise among investigators was reached when we agreed to test the prevention trial endpoint at 3 months and to analyze as for an effectiveness trial with another primary endpoint at 12 months, thus allowing for both efficacy and effectiveness analyses. The efficiency gained by having two primary endpoints is significant given that enrollment of patients into surgical trials is notoriously difficult with many refusing to relinquish the decision about a surgical procedure to chance alone.
Use of surgical sham incisions and issues of unmasking
Surgical trials present unique challenges, not typically encountered in studies evaluating medical therapy, including ethical considerations of sham procedures and the difficulty or impossibility of masking group assignment from participants, treating clinicians, and research staff. The highest standards for interventional clinical trials support the use of placebos, including sham procedures for surgical interventions. The inclusion of a sham control group in OPUS is particularly critical given that the primary outcome measures include healthrelated quality of life, an arguably subjective endpoint that may be biased by the participant's knowledge of group assignment. However, the appropriateness of surgical sham groups, given the potential invasive nature, has been questioned on ethical grounds. The network investigators debated this extensively during the design of the trial and agreed to principles put forth by Hornig and Miller [24, 25] . That is to say, a sham-controlled trial of an invasive procedure can be ethically justified if (1) there is a valuable, clinically relevant question to be answered by the research; (2) the sham control is methodologically necessary to test the study hypothesis; and (3) the risk of sham has been minimized, does not exceed the threshold of acceptable research risk, is justified by valuable knowledge to be gained, and the misleading involved in the sham is adequately disclosed and authorized by the participant during the research informed consent process. In anticipation of IRB concerns, the OPUS protocol explicitly addressed each of these criteria. For example, the protocol minimizes the risk of the sham by making only partial-thickness skin suprapubic incisions (necessary for the placement of the tension-free vaginal tape in the intervention arm) in the control arm and then requiring a standardized dressing that covers the incision for at least one week. This results in a cosmetically similar incision between the study arms, which minimizes the unmasking of randomization by participants and study staff alike. IRBs at each clinical site and the data coordinating center approved the protocol. While the protocol requires that only the study coordinators and members of the central quality of life interviewing center, blinded to treatment assignment, perform the study evaluations, another opportunity for unmasking came to light during the design of the study forms to capture healthcare cost data. It became apparent that the administrative billing data may indicate that a tension-free vaginal tape was performed. As study coordinators were tasked to gather these data, we revised the protocol so that the collection of administrative billing data would occur only after the completion of each participant's 12-month follow-up period to minimize unmasking of the study coordinators.
Considerations for measuring economic endpoints in a surgical trial
Healthcare cost is an increasingly important consideration for adopting new technologies, particularly surgical interventions. According to Anger and colleagues [26] , the total expenditure related to urinary incontinence among female Medicare beneficiaries nearly doubled between 1992 and 1998. The addition of tension-free vaginal tape at the time of prolapse repair to prevent bothersome urinary incontinence adds to the initial surgical cost, with as yet unproven benefit. Therefore, it is crucial to rigorously examine the cost-effectiveness of this prophylactic anti-incontinence procedure. The infrastructure established by this clinical trial provides an opportunity to efficiently perform a cost-effectiveness analysis with minimal bias in treatment comparisons. [27] .
One challenge encountered during the implementation of OPUS trial was the difficulty in obtaining cost data from multiple sites. Even though we requested data elements from the standard insurance claims forms (CMS-1500 and UB-04 forms), some institutions use only hard copy data forms, while others supplied electronic datasets. In cases where medical care was provided as charity, we discovered that UB-04 form was not used at all. These obviously site-specific requirements necessitated that each study team work directly with their institution's billing office to identify the format of each data element. Another challenge became apparent when some participants received follow-up medical care at facilities other than the study site. In order to collect data on these healthcare events, we developed a cost diary for participants and data report forms to explicitly collect detailed information on all medical care provided during the study period to supplement the billing data. These are reviewed with the study coordinators at each study visit.
Measuring nonparticipation bias in RCT
Another important feature of the OPUS trial is the combination of an RCT and a PPG into one overarching trial. This combination yields three important advantages over an RCT alone [28] . First, if the PPG results are comparable to those of RCT, this will enhance the external validity of RCT since patients who decline randomization represent a significant percentage of patients seen in clinical practice. Second, if the findings are inconsistent between RCT and PPG, one can describe the direction and magnitude of the bias introduced through self-selection or physician selection of treatment, a major threat to the generalizability of RCT findings. Third, the participant information gathered by inclusion of a PPG provides additional statistical power to identify factors associated with surgical outcomes [29] .
The implementation of PPG presented several challenges. We anticipated that more patients would opt for PPG than RCT as this option did not leave decisions to chance. Moreover, since the cost of each participant in PPG was approximately the same as that of one in RCT, effort was made to minimize PPG sample size. We did this in two ways. First, participants are offered PPG only after declining RCT. Second, a sampling strategy was employed such that only 60% of PPG-eligible participants could enroll at each site. To date, the number of participants who declined RCT and enrolled in the PPG remains small, indicating that most eligible patients have enrolled in RCT.
Limitations
There are several limitations to consider in our design. First, despite significant efforts at masking, participants or research staff may become aware of group assignment during the course of clinical care. For example, management of complications relatively unique to the tension-free vaginal tape procedure, such as bladder perforation, retropubic hematoma, prolonged urinary retention, or mesh erosion, may require participant unmasking. All instances of purposeful unmasking will be tracked in order to assess its potential impact on results. In addition, knowledge of group assignment by the surgeon may influence the threshold for treatment or types of treatment offered in participants who develop postoperative urinary incontinence. As randomization is also stratified by surgeon, analyses will be performed to measure this bias, if present.
Conclusion
The implementation of the OPUS trial has necessitated that investigators consider ethical issues up front, remain flexible with regard to data collection, and be constantly aware of unanticipated opportunities for unmasking. Findings from the OPUS trial will provide important information that will help surgeons to better counsel women on the benefits and risks of concomitant prophylactic anti-incontinence procedure at the time of vaginal surgery for prolapse, versus the expectant approach of treating postoperative urinary incontinence. The inclusion of cost-effectiveness analyses into surgical trials, while challenging, is necessary to inform policy makers of the incremental costs relative to the incremental benefits expected for the use of new technologies and procedures.
